Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers

Cancer

Volumn 118, Issue 6, 2012, Pages 1554-1565

  Azad, Abul Kalam ^a   Bairati, Isabelle ^b   Samson, Elodie ^b   Cheng, Dangxiao ^a   Cheng, Lu ^a   Mirshams, Maryam ^a   Savas, Sevtap ^a   Waldron, John ^a   Wang, Changshu ^c   Goldstein, David ^a   Xu, Wei ^a   Meyer, Francois ^b   Liu, Geoffrey ^a,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

DNMT3B; genetic sequence variant; head and neck cancer; secondary primary cancer; splicing

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE 5) METHYLTRANSFERASE 3 BETA; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DNA (CYTOSINE 5) METHYLTRANSFERASE 3 BETA GENE; DNA METHYLATION; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERM LINE; HAPLOTYPE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; SECOND CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

EID: 84857995726     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26446     Document Type: Article

References (39)

1. Canadian Cancer Society. Canadian Cancer Society's Steering Committee: Canadian Cancer Statistics 2009. [accessed Nov 25, 2010].
2. American Cancer Society. Cancer facts and figures 2009. [accessed Dec 15, 2010].
3. Million RR, Cassisi NJ, Clark JR,. Cancer of the head and neck. In:, DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, Penn: JB Lippincott, 1989: 488-590.
4. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989; 17: 449-456. (Pubitemid 19227546)
5. McDonald S, Haie C, Rubin P, Nelson D, Divers LD,. Second malignant tumors in patients with laryngeal carcinoma: diagnosis, treatment, and prevention. Int J Radiat Oncol Biol Phys. 1989; 17: 457-465. (Pubitemid 19227547)
6. Leon X, Ferlito A, Myer CM, 3rd et al. Second primary tumors in head and neck cancer patients. Acta Otolaryngol. 2002; 122: 765-778. (Pubitemid 35398890)
7. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2001; 10: 823-829. (Pubitemid 32738594)
8. Douglas WG, Rigual NR, Loree TR, Wiseman SM, Al-Rawi S, Hicks WL Jr,. Current concepts in the management of a second malignancy of the lung in patients with head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2003; 11: 85-88. (Pubitemid 36363690)
9. Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst. 1994; 86: 131-137. (Pubitemid 24040152)
10. Do KA, Johnson MM, Doherty DA, et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control. 2003; 14: 131-138. (Pubitemid 36539519)
11. Do KA, Johnson MM, Lee JJ, et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004; 101: 2837-2842. (Pubitemid 39603192)
12. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ,. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer. 2006; 106: 2636-2644.
13. Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM,. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope. 2005; 115: 2221-2231. (Pubitemid 44391640)
14. Hopkins J, Cescon DW, Tse D, et al. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev. 2008; 17: 490-499. (Pubitemid 351469197)
15. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst. 2005; 97: 481-488. (Pubitemid 40590429)
16. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005; 23: 5805-5813.
17. Meyer F, Fortin A, Gelinas M, et al. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol. 2009; 27: 2970-2976.
18. Warren S, Gates O,. Multiple primary malignant tumor: a survey of the literature and a statistical study. Am J Cancer. 1932; 16: 1358-1414.
19. Lefor AT, Bredenberg CE, Kellman RM, Aust JC,. Multiple malignancies of the lung and head and neck. Second primary tumor or metastasis? Arch Surg. 1986; 121: 265-270. (Pubitemid 16105178)
20. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990; 323: 795-801. (Pubitemid 20303877)
21. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C,. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009; 37: e67.
22. Momparler RL, Bovenzi V,. DNA methylation and cancer. J Cell Physiol. 2000; 183: 145-154. (Pubitemid 30185933)
23. Liu Z, Wang L, Wang LE, Sturgis EM, Wei Q,. Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2008; 268: 158-165.
24. Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q,. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002; 62: 4992-4995. (Pubitemid 34984424)
25. Chang KP, Hao SP, Liu CT, et al. Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study. Oral Oncol. 2007; 43: 345-351.
26. Fackenthal JD, Godley LA,. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech. 2008; 1: 37-42.
27. Teodoridis JM, Hall J, Marsh S, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005; 65: 8961-8967. (Pubitemid 41377387)
28. Lee SJ, Jeon HS, Jang JS, et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis. 2005; 26: 403-409. (Pubitemid 40246562)
29. Wang L, Rodriguez M, Yue P, Sun SY, Hong WK, Mao L,. Polymorphsims in DNMT3B6 promoter region and lung cancer risk. Proc Am Assoc Cancer Res. 2001; 42: 863.
30. Montgomery KG, Liu MC, Eccles DM, Campbell IG,. The DNMT3B C→T promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Res. 2004; 6: R390-R394.
31. Fan H, Zhang F, Hu J, Liu D, Zhao Z,. Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study. J Exp Clin Cancer Res. 2008; 27: 24.
32. Issa JP, Baylin SB, Belinsky SA,. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 1996; 56: 3655-3658. (Pubitemid 26272007)
33. Belinsky SA, Nikula KJ, Baylin SB, Issa JP,. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA. 1996; 93: 4045-4050. (Pubitemid 26144243)
34. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA,. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ. 1996; 313: 716-721. (Pubitemid 26313071)
35. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356: 1944-1956. (Pubitemid 46740304)
36. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
37. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I,. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol. 29: 739-746.
38. Perez-Ordonez B, Beauchemin M, Jordan RC,. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006; 59: 445-453.
39. Zhang Y, Sturgis EM, Zafereo ME, Wei Q, Li G,. p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Cancer. 117: 1227-1235.